every time I see a headline like this I always ask - which cancers - for whom - what's the trial size - what's the success rate - what's the cost the arti

every time I see a headline like this I always ask - which cancers - for whom - what's the trial size - what's the success rate - what's the cost the article answers some, to some degree: - for "leukaemias, lymphomas and myelomas" - not many; "relatively few US centres are capable of delivering it", "For people with lymphoma, the figure is around 1 in 5" people who could benefit are receiving it [1] - "tens of thousands" - "only about 25-35% of CAR-T cell recipients with chronic lymphocytic leukaemia experienced a complete remission" - as of 2021 per Prime Therapeutics, "Although the wholesale acquisition cost of chimeric antigen receptor (CAR) T-cell therapies to treat B-cell lymphoma is $373,000, a new study by Prime Therapeutics of real-world data found that the total cost averages more than $700,000 and can exceed $1 million in some cases." [2] [1] https://www.nature.com/articles/d41586-020-02675-w https://www.nature.com/articles/d41586-020-02675-w [2] https://www.pharmacytimes.com/view/study-finds-total-cost-of-care-for-car-t-post-treatment-events-can-exceed-1-million https://www.pharmacytimes.com/view/study-finds-total-cost-of...